Boston Scientific to Acquire Nalu Medical - Gilde Healthcare

Menu
Menu
Home

Boston Scientific to Acquire Nalu Medical

Geoff Pardo

General Partner Healthtech
Venture&Growth
United States of America

Karthik Bolisetty

Investment Manager Healthtech
Venture&Growth
United States of America
October 17, 2025
Utrecht (the Netherlands) & Boston, MA (United States)

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation.

Nalu Medical markets a miniaturized implantable neurostimulation device to treat patients with chronic neuropathic pain.
Boston Scientific expects to complete the transaction in the first half of 2026, subject to customary closing conditions.

Gilde Healthcare co led the $104m financing round in 2022 and Geoff Pardo serves on the Board of Directors.

Press Release

More news

Gilde Healthcare launches Climate Solutions fund realizing initial close at €250M

With commitments from international pension funds, banks, fund-of-funds, endowments and family offices, Gilde Healthcare realizes an initial close at €250 million Expansion into Climate Solutions builds on Gilde Healthcare’s track record in impactful investing and...
February 18, 2026

Gilde Healthcare Company Big Health Secures Funding to Accelerate Adoption of Digital Mental Health Treatments

New investment fuels expansion as leading health systems adopt evidence-based digital care, driven by new billing codes and strong demand for proven mental health solutions. Big Health, a leading developer of digital treatments for the...
February 12, 2026

Gilde Healthcare company SpyGlass Pharma announces pricing of initial public offering at NASDAQ

SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per...
February 6, 2026